A detailed history of Fin Trust Capital Advisors, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Fin Trust Capital Advisors, LLC holds 1,811 shares of EXEL stock, worth $64,489. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,811
Previous 1,811 -0.0%
Holding current value
$64,489
Previous $40,000 15.0%
% of portfolio
0.01%
Previous 0.01%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 02, 2024

SELL
$20.17 - $23.93 $201,700 - $239,300
-10,000 Reduced 84.67%
1,811 $42,000
Q4 2023

Feb 13, 2024

BUY
$19.25 - $24.13 $192,211 - $240,938
9,985 Added 546.82%
11,811 $283,000
Q3 2023

Oct 24, 2023

BUY
$19.04 - $22.74 $6,740 - $8,049
354 Added 24.05%
1,826 $39,000
Q3 2022

Oct 20, 2022

BUY
$15.68 - $22.27 $3,935 - $5,589
251 Added 20.56%
1,472 $24,000
Q2 2022

Jul 26, 2022

SELL
$17.44 - $23.16 $209 - $277
-12 Reduced 0.97%
1,221 $25,000
Q1 2022

May 03, 2022

BUY
$17.03 - $22.67 $1,600 - $2,130
94 Added 8.25%
1,233 $28,000
Q4 2021

Feb 14, 2022

BUY
$15.84 - $21.88 $7,128 - $9,846
450 Added 65.31%
1,139 $21,000
Q1 2021

May 17, 2021

SELL
$20.53 - $25.22 $4,578 - $5,624
-223 Reduced 24.45%
689 $16,000
Q4 2020

Feb 16, 2021

SELL
$18.39 - $24.8 $5,075 - $6,844
-276 Reduced 23.23%
912 $18,000
Q3 2020

Nov 10, 2020

SELL
$20.67 - $26.94 $29,103 - $37,931
-1,408 Reduced 54.24%
1,188 $29,000
Q2 2020

Sep 11, 2020

BUY
$16.46 - $27.42 $42,730 - $71,182
2,596 New
2,596 $62,000
Q2 2020

Aug 14, 2020

SELL
$16.46 - $27.42 $21,315 - $35,508
-1,295 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$14.46 - $21.8 $8,126 - $12,251
562 Added 76.67%
1,295 $22,000
Q4 2019

Jan 23, 2020

SELL
$15.15 - $18.89 $9,923 - $12,372
-655 Reduced 47.19%
733 $13,000
Q3 2019

Oct 29, 2019

SELL
$17.68 - $22.65 $19,677 - $25,209
-1,113 Reduced 44.5%
1,388 $25,000
Q2 2019

Aug 01, 2019

SELL
$18.93 - $24.75 $605 - $792
-32 Reduced 1.26%
2,501 $53,000
Q1 2019

May 09, 2019

BUY
$19.6 - $24.76 $27,479 - $34,713
1,402 Added 123.96%
2,533 $61,000
Q4 2018

Feb 11, 2019

BUY
$13.65 - $21.8 $15,438 - $24,655
1,131 New
1,131 $22,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.5B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Fin Trust Capital Advisors, LLC Portfolio

Follow Fin Trust Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fin Trust Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fin Trust Capital Advisors, LLC with notifications on news.